IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice.

[1]  R. Pacifici,et al.  T Cell–Expressed CD40L Potentiates the Bone Anabolic Activity of Intermittent PTH Treatment , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  Guang-bin Wang,et al.  Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis , 2015, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[3]  R. Weinstein,et al.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. , 2014, Bone.

[4]  D. Baeten,et al.  The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis , 2014, Current opinion in rheumatology.

[5]  M. Genovese,et al.  Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. , 2014, The New England journal of medicine.

[6]  R. Komsa-Penkova,et al.  Interleukin-17 producing T cells could be a marker for patients with allergic rhinitis. , 2014, The Israel Medical Association journal : IMAJ.

[7]  L. Plotkin,et al.  Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. , 2014, Endocrinology.

[8]  I. Molnár,et al.  IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis , 2014, Osteoporosis International.

[9]  K. Lu,et al.  Correlation of Interleukin-17-Producing Effector Memory T Cells and CD4+CD25+Foxp3 Regulatory T Cells with the Phosphate Levels in Chronic Hemodialysis Patients , 2014, TheScientificWorldJournal.

[10]  L. Mccauley,et al.  Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone , 2014, Proceedings of the National Academy of Sciences.

[11]  R. Brandes,et al.  L-Type Calcium Channel Inhibitor Diltiazem Prevents Aneurysm Formation by Blood Pressure–Independent Anti-Inflammatory Effects , 2013, Hypertension.

[12]  Richard W. Martin,et al.  A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis , 2013, Arthritis Research & Therapy.

[13]  R. Baron,et al.  Parathyroid Hormone (PTH)/PTH-related Peptide Type 1 Receptor (PPR) Signaling in Osteocytes Regulates Anabolic and Catabolic Skeletal Responses to PTH* , 2013, The Journal of Biological Chemistry.

[14]  R. Pacifici.  Role of T cells in the modulation of PTH action: physiological and clinical significance , 2013, Endocrine.

[15]  R. D. Hatton,et al.  The Th17 family: flexibility follows function , 2013, Immunological reviews.

[16]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Hui Wang,et al.  TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1β-induced rat osteoarthritis chondrocytes in vitro , 2012, Arthritis Research & Therapy.

[18]  R. Trivedi,et al.  Estrogen Deficiency Induces the Differentiation of IL-17 Secreting Th17 Cells: A New Candidate in the Pathogenesis of Osteoporosis , 2012, PloS one.

[19]  W. Zou,et al.  IL‐17 mediates estrogen‐deficient osteoporosis in an Act1‐dependent manner , 2012, Journal of cellular biochemistry.

[20]  M. Mochizuki,et al.  Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease , 2012, Arthritis Research & Therapy.

[21]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[22]  K. Baek,et al.  Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH , 2012, Proceedings of the National Academy of Sciences.

[23]  P. Insel,et al.  Divergent requirement for Gαs and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets. , 2012, The Journal of clinical investigation.

[24]  R. Taichman,et al.  An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. , 2011, Endocrinology.

[25]  A. Waisman.  T helper cell populations: As flexible as the skin? , 2011, European journal of immunology.

[26]  Chi-Chen Lin,et al.  Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy , 2011, Arthritis research & therapy.

[27]  J. Zepp,et al.  IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. , 2011, Trends in immunology.

[28]  S. Nakae,et al.  Functional specialization of interleukin-17 family members. , 2011, Immunity.

[29]  A. Horvai,et al.  Metabolic bone diseases. , 2011, Seminars in diagnostic pathology.

[30]  J. Hell.  β-Adrenergic Regulation of the L-Type Ca2+ Channel CaV1.2 by PKA Rekindles Excitement , 2010, Science Signaling.

[31]  H. Kronenberg,et al.  Disruption of PTH Receptor 1 in T Cells Protects against PTH-Induced Bone Loss , 2010, PloS one.

[32]  T. Mcclanahan,et al.  Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors , 2010, Arthritis research & therapy.

[33]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[34]  R. Guldberg,et al.  T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. , 2009, Cell metabolism.

[35]  M. Oh‐hora.  Calcium signaling in the development and function of T‐lineage cells , 2009, Immunological reviews.

[36]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[37]  A. Abou-Samra,et al.  PTH and PTHrP signaling in osteoblasts. , 2009, Cellular signalling.

[38]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[39]  Christopher G. King,et al.  IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.

[40]  R. Nurieva,et al.  Regulation and Function of Proinflammatory TH17 Cells , 2008, Annals of the New York Academy of Sciences.

[41]  M. Terauchi,et al.  T cells potentiate PTH-induced cortical bone loss through CD40L signaling. , 2008, Cell metabolism.

[42]  G. Berry,et al.  Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. , 2007, Blood.

[43]  Y. Kadono,et al.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006, The Journal of experimental medicine.

[44]  J. Flynn,et al.  IL-17 Production Is Dominated by γδ T Cells rather than CD4 T Cells during Mycobacterium tuberculosis Infection1 , 2006, The Journal of Immunology.

[45]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[46]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[47]  R. Lindsay,et al.  Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. , 2005, The Journal of endocrinology.

[48]  L. Qin,et al.  Parathyroid hormone: a double-edged sword for bone metabolism , 2004, Trends in Endocrinology & Metabolism.

[49]  R. L. Cain,et al.  Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. , 2001, Endocrinology.

[50]  J. Shellito,et al.  Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.

[51]  R. Baron,et al.  Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. , 2001, The Journal of clinical investigation.

[52]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[53]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[54]  Yulan He,et al.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. , 1998, Journal of immunology.

[55]  L. Aarden,et al.  Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. , 1989, Biochemical and biophysical research communications.

[56]  T. Clemens,et al.  Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  E. Shen,et al.  The effect of aging on the frequency, phenotype and cytokine production of human blood CD4 + CXCR5 + T follicular helper cells: comparison of aged and young subjects , 2014, Immunity & ageing : I & A.

[58]  H. Takayanagi,et al.  Autoimmune arthritis: the interface between the immune system and joints. , 2012, Advances in immunology.

[59]  J. Flynn,et al.  IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. , 2006, Journal of immunology.

[60]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[61]  D. Dempster,et al.  CHAPTER 26 – Histomorphometric Analysis of Bone in Primary Hyperparathyroidism , 2001 .

[62]  F. Kuhlencordt,et al.  [Primary hyperparathyroidism]. , 1979, Deutsche medizinische Wochenschrift.

[63]  J. Dequeker,et al.  [Metabolic bone diseases]. , 1973, Rhode Island dental journal.

[64]  J. Potts,et al.  THE PARATHYROIDS. , 1964, Advances in metabolic disorders.